Information  X 
Enter a valid email address

Xenova Group PLC (XEN)

  Print      Mail a friend

Tuesday 30 October, 2001

Xenova Group PLC

Appointment

Xenova Group PLC
30 October 2001

For Immediate Release



                               Xenova Group plc


           Board Changes and Appointment of New Commercial Director



Slough, UK, 30th October 2001 - Xenova Group plc (Nasdaq NM: XNVA; London
Stock Exchange: XEN) today announced that Commercial Director Mr Nick Hart
will resign from the Board effective 31 December 2001. He will remain with
Xenova on a part time basis for a short period after 31 December.  Mr Hart
will be joining UK-based Bioscience Managers Limited, a corporate and
investment advisory firm specialising in the life science sector.  He joined
Xenova following the merger with Cantab Pharmaceuticals plc (Cantab) in April
2001.  Mr Hart joined Cantab as Finance Director in 1990 and was acting Chief
Executive of Cantab during the period immediately prior to the Xenova/Cantab
merger.



Dr Joy Barton will join Xenova on 5 November 2001 as Commercial Director,
based at Slough, UK and will become a member of the senior management team.
Dr Barton joins Xenova from Accenture, (formerly Andersen Consulting), where
she has specialised in providing consultancy to the pharmaceutical industry on
the commercialisation of key products resulting from research & development.



Dr Stephen Inglis will also resign from the Board effective 31 December 2001
in order to take up an appointment as Director of the National Institute of
Biological Standards and Control (NIBSC).  Dr Inglis joined Xenova as Research
Director, Biologics, following the merger with Cantab in April 2001.  He was
previously Research Director, Cantab.  Before joining Cantab in 1989 as Head
of Molecular Sciences, he was a lecturer in Virology in the Department of
Pathology at Cambridge University.



David Oxlade, Xenova's Chief Executive Officer, commented:



'Nick and Stephen have made a considerable contribution to the successful
merger completed earlier this year, and will be missed.  We wish them every
success in their new roles and thank them both for their significant
contributions to both Cantab and more recently Xenova. I also welcome Joy to
Xenova; her specialist commercial experience in the pharmaceutical field will
be of great value to our team.'





                                    -end-





                                   Contacts


UK
Xenova Group plc                                  Financial Dynamics
Tel: +44 (0) 1753 706600                          Tel: +44 (0) 207 831 3113
David Oxlade: Chief Executive Officer             David Yates/Fiona Noblet
Daniel Abrams: Finance Director
John St Clair Roberts: Medical Director

Hilary Reid Evans: Corporate Communications


US

BMC  Communications

Tel: 001 212 477 9007

Brad Miles (Ext 17)/Lauren Tortorete (Ext 20)



Notes to Editors



Xenova's product pipeline focuses principally on the therapeutic areas of
cancer, infectious, autoimmune and cardiovascular diseases.  The Group has a
well-established track record in the identification, development and
partnering of innovative products and technologies.  Xenova has partnerships
with a number of major pharmaceutical companies including Lilly, Pfizer,
Celltech and QLT Inc.



For further information about Xenova and its products please visit the Xenova
website at www.xenova.co.uk.



Safe Harbor Statement under the US Private Securities Litigation Reform Act of
1995: Some or all of the statements in this document that relate to future
plans, expectations, events, performances and the like are forward-looking
statements, as defined in the US Private Securities Litigation Reform Act of
1995.  Actual results of events could differ materially from those described
in the forward-looking statements due to a variety of factors, including those
set forth in the Company's filings with the US Securities and Exchange
Commission.